Mammoth Biosciences raises $45 mln to 基金 押し進める into CRISPR-based therapies
Jan 30 (Reuters) - California-based biotech startup Mammoth Biosciences said on Thursday it had raised $45 million in a series B 基金ing 一連の会議、交渉／完成する as it looks to 拡大する the use of its CRISPR-based 科学（工学）技術 from diagnostics to developing new therapies.
CRISPR 科学（工学）技術 typically 言及するs to 遺伝子 editing 道具s - with CRISPR/Cas9 as the most 目だつ example - which work as a 肉親，親類d of molecular scissor to 削減する away unwanted pieces of genetic 構成要素 and 取って代わる them with new ones.
"While it's not wrong to think of CRISPR as a pair of scissors, I think it's incomplete," company co-創立者 Trevor ツバメ said.
"CRISPR is a programmable way of getting the protein where you want it on the デオキシリボ核酸. It's more like a search engine."
Mammoth, which was co-設立するd by 早期に 遺伝子 editing 開拓する Jennifer Doudna, was the first to develop a CRISPR 壇・綱領・公約 as a 病気 （犯罪，病気などの）発見 system.
The company also uses its 壇・綱領・公約 to discover new proteins and, with the 基金ing, hopes to 押し進める those into 臨床の 裁判，公判s.
Mammoth is 最初 焦点（を合わせる）ing on 共同s to 前進する its 実験の therapies, as …に反対するd to developing the proteins into a viable therapy on its own.
"Long 称する，呼ぶ／期間／用語, that's a 肉親，親類d of obvious direction for Mammoth to go. But I think 権利 now we're 焦点（を合わせる）d on walking before we run, and we're very 利益／興味d in doing 共同s with experienced partners in this space," ツバメ told Reuters.
The 基金ing 一連の会議、交渉／完成する, led by Decheng 資本／首都, 含むs Alphabet Inc's 生命科学s 分割 Verily as a new 投資家.
With the new 一連の会議、交渉／完成する, the company has now raised over $70 million in 基金ing.
(報告（する）／憶測ing by マナs Mishra in Bengaluru; Editing by Krishna Chandra Eluri)
